The University of Michigan Comprehensive Cancer Center (UMCCC) is one of the nation's premiere multidisciplinary cancer research programs, with a long Institutional tradition of excellence in patient and population-based research. The Patient and Population Core is a new cancer center core resource that has been developed as a result of UMCCC's strategic planning to meet key needs of cancer center researchers identified through a strategic planning process. Programs in cancer prevention and control, clinical research, and basic science all require enhanced access to annotated patient and population data with accompanying DNA samples In order to continue the cancer center's mission and commitment to achieve innovative research in personalized cancer prevention, diagnosis and treatment. The Patient and Population Core is a resource that collects, catalogs, and stores DNA samples together with highly annotated, linked clinical and epidemiologic Information from cancer patients and representative controls without cancer. Building upon an already established cancer center infrastructure and health-system wide institutional commitment to biobanking, the Patient and Population Core takes advantage of the combined resources of the Michigan Institute for Clinical Health Research (MICHR) Biorepository and the Michigan Clinical Research Unit (MCRU) to provide cancer-specific resources to members of the cancer center, This resource will facilitate environmental, susceptibility, prognostic, and mechanistic studies to be conducted by researchers from various disciplines within the cancer center, as well as provide opportunities for pilot studies and resources for successful grant submissions for translational and molecular epidemiologic research studies, by linking specimen data with questionnaire and medical record data. The overall goal of this core is to further empower our investigators, promote resource sharing, and maximize the value of data and DNA sample collection for research participants, investigators, UMCCC members, and our funding agencies. Since its inception in April 2010, DNA samples and data from 3,910 patients have been established within the Patient and Population Core repository, and 7 cancer center members have accessed DNA samples and data. CCSG funding comprises 36% of the proposed core budget, with the remaining support from charge-backs at rates determined by institution-wide metrics and other institutional support.
The Patient and Population Core is dedicated to providing a biolibrary for cancer researchers to understand the causes and cures of cancer. By creating an exceptional resource that contains both data and biosamples of patients with cancer and healthy individuals at risk of cancer, the Patient and Population Core directly contributes to the public health mission of the University of Michigan Comprehensive Cancer Center.
|Owen, John Henry; Graham, Martin P; Chinn, Steven B et al. (2016) Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck 38 Suppl 1:E459-67|
|Lee, Alice W; Ness, Roberta B; Roman, Lynda D et al. (2016) Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol 127:828-36|
|Mathewson, Nathan D; Jenq, Robert; Mathew, Anna V et al. (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-13|
|Boonstra, Philip S; Mukherjee, Bhramar; Gruber, Stephen B et al. (2016) Tests for Gene-Environment Interactions and Joint Effects With Exposure Misclassification. Am J Epidemiol 183:237-47|
|Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65|
|Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46|
|Boonstra, Philip S; Taylor, Jeremy M G; Smolska-Ciszewska, Beata et al. (2016) Alpha/beta (Î±/Î²) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol 89:20150957|
|Amin, Nisar A; Malek, Sami N (2016) Gene mutations in chronic lymphocytic leukemia. Semin Oncol 43:215-21|
|Hardiman, Karin M; Ulintz, Peter J; Kuick, Rork D et al. (2016) Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest 96:4-15|
|Zhao, Ende; Maj, Tomasz; Kryczek, Ilona et al. (2016) Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 17:95-103|
Showing the most recent 10 out of 1165 publications